D-1040-2017 Class II Terminated
FDA drug recall D-1040-2017 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jul 12, 2017 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Jan 14, 2019). Affected quantity: 120 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 9, 2017
- Initiation Date
- Jul 12, 2017
- Termination Date
- Jan 14, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 120 vials
Product description
Testosterone Cypionate + Progesterone, 200 mg/ 2.5 mg/mL ,10 mL amber glass vials, Rx Only, Compounded by AXIA Pharmaceutical, Los Angeles, CA 90025
Reason for recall
CGMP Deviations
Distribution pattern
There were only one customer in California
Code information
Lot # 03022017+44906; BUD 08/29/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1040-2017
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026